Research using advanced MRI techniques shows that COVID-19 can cause lasting changes in the brain even after full recovery, potentially leading to long-term neurological effects and cognitive issues, regardless of ongoing symptoms.
A Yale study suggests that SARS-CoV-2 can induce amyloid beta buildup in retinal tissue, which is associated with Alzheimer's disease, and highlights the potential of targeting NRP1 to prevent neurological complications like brain fog following COVID-19.
Researchers from Trinity College Dublin and FutureNeuro have discovered a link between Long COVID and brain fog, identifying disruption to the integrity of blood vessels in the brains of affected patients. This breakthrough finding offers new insights for diagnosing and treating the condition, potentially transforming the approach to post-viral neurological syndromes. The study, published in Nature Neuroscience, suggests that leaky blood vessels in the brain, in tandem with a hyperactive immune system, may be the key drivers of brain fog associated with Long COVID, paving the way for targeted therapies in the future.
A recent study has highlighted the potential long-term neurological effects of COVID-19. Researchers used preclinical mouse models and human post-mortem samples to study the presence and distribution pattern of the SARS-CoV-2 spike protein in the skull-meninges-brain axis. They found a substantial accumulation of the protein in the niches of human skull marrow, meninges, skull-meninges connection, and brain parenchyma in both mouse and human-origin samples. The study data suggested a mechanism for SARS-CoV-2 entry into the CNS, and the researchers identified several proteins that could be leveraged as therapeutic targets.